{"id":4945,"date":"2019-05-02T11:06:22","date_gmt":"2019-05-02T05:36:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4945"},"modified":"2021-07-24T12:57:19","modified_gmt":"2021-07-24T07:27:19","slug":"the-business-cocktail-lemborexant","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a311b23b2bf7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a311b23b2bf7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant\/#EISAI_now_solely_responsible_for_lemborexant\" >EISAI now solely responsible\nfor lemborexant<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant\/#Keytruda_contributes_to_Mercks_fortune\" >Keytruda contributes\nto Merck\u2019s fortune<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant\/#BenevolentAI_and_AstraZeneca_to_accelerate_Drug_Discover_using_AI\" >BenevolentAI and\nAstraZeneca to accelerate Drug Discover using AI<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant\/#Exosome_focused_Codiak_Biosciences_files_for_IPO\" >Exosome focused\nCodiak Biosciences files for IPO<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"EISAI_now_solely_responsible_for_lemborexant\"><\/span><strong>EISAI now solely responsible\nfor<\/strong> <strong>lemborexant<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Eisai<\/strong> today announced that its U.S. subsidiary has bought out \u00a0<strong>Purdue Pharma<\/strong> L.P.\u2019s rights in the worldwide collaboration for the development and commercialization of <strong>lemborexant<\/strong>, an investigational sleep-wake regulation agent being studied for the treatment of multiple <strong>sleep-wake disorders<\/strong>, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/insomnia-market\"><strong>insomnia<\/strong> <\/a>and irregular <strong>sleep-wake rhythm disorder (ISWRD)<\/strong> in patients with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s <\/a>Disease<\/strong>. Eisai will through a one-time payment to Purdue, will make Purdue no longer a participant or fund-raiser for the development and commercialization of lemborexant.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Keytruda_contributes_to_Mercks_fortune\"><\/span><strong>Keytruda contributes\nto Merck\u2019s fortune<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>A steep increase in the sales of <strong>Keytruda<\/strong> has led <strong>Merck<\/strong> &amp; Co.\u2019s sales growth a significant raise. The expectation for sales to grow between <strong>4% and 7%<\/strong> have been put forward, a little up from the previous projection of a 2% to 6% increase. <strong>Keytruda <\/strong>being the chief contributor has outpaced the <strong>Bristol-Myers Squibb&#8217;s <\/strong>rival drug <strong>Opdivo<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BenevolentAI_and_AstraZeneca_to_accelerate_Drug_Discover_using_AI\"><\/span><strong>BenevolentAI and\nAstraZeneca to accelerate Drug Discover using AI<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>BenevolentAI<\/strong> to accelerate the use of <a href=\"https:\/\/www.delveinsight.com\/blog\/wearable\/\">Artificial Intelligence<\/a> and Machine learning for the development of new treatments for <strong>chronic kidney disease<\/strong> (CKD) and <strong>idiopathic pulmonary fibrosis<\/strong> (IPF) has inked an agreement with <strong>AstraZeneca. <\/strong>The two organization has collaborated to work together by combining <strong>AstraZeneca<\/strong>\u2019s genomics, chemistry and clinical data with <strong>BenevolentAI\u2019s<\/strong> target identification platform and biomedical knowledge graph.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Exosome_focused_Codiak_Biosciences_files_for_IPO\"><\/span><strong>Exosome focused\nCodiak Biosciences files for IPO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Codiak BioSciences<\/strong> has filed a prospectus to raise up to <strong>USD 86 million<\/strong> in an initial public offering. The Cambridge based company plans to list on the Nasdaq under the symbol<strong> CDAK<\/strong>. The initial focus of the company will be targeting of immune cells, including antigen presenting cells, T cells and <strong>natural killer cells,<\/strong> <strong>monocytes <\/strong>and <strong>macrophages<\/strong>, and <strong>B lymphocytes<\/strong>, or <strong>B cells<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out \u00a0Purdue Pharma L.P.\u2019s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4947,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17629,72,96,130,17708,1541,345,395],"industry":[17225],"therapeutic_areas":[17245,17228],"class_list":{"0":"post-4945","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","6":"hentry","7":"category-notizia","8":"tag-alzheimers-disease","10":"tag-astrazeneca","11":"tag-bristol-myers-squibb","12":"tag-codiak-biosciences","13":"tag-eisai","14":"tag-keytruda","15":"tag-merck","16":"industry-pharmaceutical","17":"therapeutic_areas-neurology","18":"therapeutic_areas-oncology"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Business Cocktail 02\/05\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Eisai today announced that ithas bought out Purdue Pharma L.P.\u2019s rights for the development and commercialisation of lemborexant...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business Cocktail 02\/05\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Eisai today announced that ithas bought out Purdue Pharma L.P.\u2019s rights for the development and commercialisation of lemborexant...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-02T05:36:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17135656\/Lorem.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business Cocktail 02\/05\/2019 - DelveInsight Business Research","description":"Eisai today announced that ithas bought out Purdue Pharma L.P.\u2019s rights for the development and commercialisation of lemborexant...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant","og_locale":"en_US","og_type":"article","og_title":"The Business Cocktail 02\/05\/2019 - DelveInsight Business Research","og_description":"Eisai today announced that ithas bought out Purdue Pharma L.P.\u2019s rights for the development and commercialisation of lemborexant...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-02T05:36:22+00:00","article_modified_time":"2021-07-24T07:27:19+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17135656\/Lorem.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant","name":"The Business Cocktail 02\/05\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17135656\/Lorem.png","datePublished":"2019-05-02T05:36:22+00:00","dateModified":"2021-07-24T07:27:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Eisai today announced that ithas bought out Purdue Pharma L.P.\u2019s rights for the development and commercialisation of lemborexant...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-lemborexant#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17135656\/Lorem.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17135656\/Lorem.png","width":647,"height":345,"caption":"the business cocktail lemborexant"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17135656\/Lorem-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Codiak Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eisai<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Codiak Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Eisai<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 2, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 2, 2019 11:06 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"the business cocktail lemborexant","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4945"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4945\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4947"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4945"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4945"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}